[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Capitol Health Call
September 8, 2010

Rare Pediatric Diseases

JAMA. 2010;304(10):1060. doi:10.1001/jama.2010.1283

Private-sector innovation aimed at treating rare and neglected pediatric diseases may be spurred on by a Senate bill introduced August 4.

The bill (S 3697 [http://thomas.loc.gov]), introduced by Sen Sherrod Brown (D, Ohio) and cosponsored by Sen Sam Brownback (R, Kan) and Al Franken (D, Minn), amends provisions of the Food and Drug Administration Amendments Act that established an incentive for pharmaceutical companies to develop innovative therapeutics for neglected tropical diseases. Under the law, a company that develops new drugs and biologics for neglected tropical diseases is eligible for a “priority review voucher” that entitles it to expedited review of another drug submitted for approval. The bill extends the same voucher program to rare and neglected pediatric diseases.

First Page Preview View Large
First page PDF preview
First page PDF preview